Micron Biomedical Inc.

Micron Biomedical Inc., a for-profit corporation headquartered in Alpharetta, Georgia, manufactures dissolving microneedle patch medical devices for federal health research and public health procurement, operating exclusively as a prime contractor with no subcontract footprint or federal IDV seats.

The vendor's entire federal customer base concentrates within the Department of Health and Human Services across two entities. The National Institute of Allergy and Infectious Diseases holds the largest single award: a $4.5 million cost-plus-fixed-fee definitive contract awarded July 1, 2026, for development of a toll-like receptor 5 agonist dissolving microneedle patch for radiation and nuclear medical countermeasures and biodosimetry applications, running through June 30, 2029. The CDC's Pittsburgh office anchors the remainder of the footprint with eight awards totaling $2.3 million in combined potential value, including a $620,008 firm fixed-price definitive contract awarded September 15, 2026, for manufacturing of a dissolving microneedle patch to administer rotavirus vaccine (completion September 14, 2028), and two purchase orders for general microneedle patch procurement awarded September 2023 and September 2024, each valued at $249,999. Across its nine prime awards spanning 2016 through September 2026, Micron Biomedical has obligated $3.8 million against a combined potential value of $6.8 million. No awards carry set-aside designations; the vendor competes full-and-open. Work is performed at the company's Atlanta, Georgia facility. One award valued at $620 thousand faces ultimate completion inside the next twenty-four months and therefore enters recompete. The vendor's capability portfolio, grounded in biotechnology research and development across NAICS codes emphasizing applied research in life sciences, centers on custom dissolving microneedle patch design and manufacturing for vaccine delivery and medical countermeasures applications.